ENTITY
Hua Medicine

Hua Medicine (2552 HK)

32
Analysis
Health Care • China
Hua Medicine is an innovative drug development and commercialization company focused on novel therapies for patients with unmet medical needs, particularly in diabetes care. Its cornerstone product is HuaTangNing (dorzagliatin tablets), a first-in-class oral drug for the treatment of Type 2 diabetes. The company was founded in 2011 and is headquartered in Shanghai, China.
more
bearish•Babytree
•19 Nov 2018 11:47

Last Week in GER Research: Babytree, NTT, Tongcheng, IDreamSky, Fosun, Sinochem, and Mogu

Below is a recap of the key IPO and event-driven research produced by the Global Equity Research team. This week we highlight the latest on...

Logo
781 Views
Share
bearish•Softbank Group
•12 Nov 2018 06:05

Last Week in GER Research: Softbank, Haidilao, Tongcheng-Elong, Ctrip and 360 Finance

Below is a recap of the key IPO and event-driven research produced by the Global Equity Research team.Ā Ā This week we update on Softbank Group (9984...

Logo
467 Views
Share
bearish•Softbank Group
•05 Nov 2018 06:03

Last Week in GER Research: Softbank, Babytree, Tencent Music, MYOB, Yancoal, Spotify Warning & More!

Below is a recap of the key IPO and event-driven research produced by the Global Equity Research team.Ā  Last week, Arun initiated IPO coverage...

Logo
437 Views
Share
bearish•Innovent Biologics
•31 Oct 2018 16:39

Innovent Biologics IPO First-Day: Take Money off the Table

Despite a recentĀ spell of lacklustre early-stage biotech flotations that have slumpedĀ post-IPO, Innovent Biologics Inc (1801 HK)'s shares popped...

Logo
721 Views
Share
bearish•Babytree
•27 Oct 2018 16:59

Last Week in GER Research: A Dancing Tesla, Babytree, Mobvista, TuanChe and Pintec

Below is a recap of the key IPO and event-driven research produced by the Global Equity Research team. This week we recap on polarizedĀ Tesla Motors...

Logo
558 Views
Share
x